Gangolli Julian S
SEC insider (Form 3/4/5 filer). CIK 0001532023. Director at Krystal Biotech, Inc. (KRYS) and 2 other issuers. 8 reported Form 4/5 transactions since Sep 2024; latest on Sep 14, 2026. Located in PITTSBURGH, PA.
Companies Gangolli Julian S has filed insider reports for
- Krystal Biotech, Inc. (KRYS): Director
- Outlook Therapeutics, Inc. (OTLK): Director
- Revance Therapeutics, Inc. (RVNC): Director
Gangolli Julian S
CIK: 0001532023
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Sep 14, 2026KRYS
Krystal Biotech, Inc.
AwardDirectStock Option (Right to Buy)
1.2K shares- - Sep 14, 2026KRYS
Krystal Biotech, Inc.
AwardDirectRestricted Stock Units
471 shares- - Oct 1, 2025OTLK
Outlook Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
286.7K shares- - Jun 30, 2025KRYS
Krystal Biotech, Inc.
AwardDirectStock Option (Right to Buy)
5K shares- - Feb 6, 2025RVNC
Revance Therapeutics, Inc.
DispositionDirect15K shares- - Feb 4, 2025RVNC
Revance Therapeutics, Inc.
Tender OfferDirect30.1K shares at avg. $3.65$110K - Oct 1, 2024OTLK
Outlook Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
71.2K shares- - Oct 1, 2024OTLK
Outlook Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
56.6K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 14, 2026 |  KRYS Krystal Biotech, Inc. | Award Stock Option (Right to Buy) | 1,187 | - | - | Direct |
| Sep 14, 2026 | KRYS Krystal Biotech, Inc. | Award Restricted Stock Units | 471 | - | - | Direct |
| Oct 1, 2025 |  OTLK Outlook Therapeutics, Inc. | Award Stock Option (Right to Buy) | 286,734 | - | - | Direct |
| Jun 30, 2025 | KRYS Krystal Biotech, Inc. | Award Stock Option (Right to Buy) | 5,000 | - | - | Direct |
| Feb 6, 2025 |  RVNC Revance Therapeutics, Inc. | Disposition | 15,000 | - | - | Direct |
| Feb 4, 2025 | RVNC Revance Therapeutics, Inc. | Tender Offer | 30,106 | $3.65 | $109,887 | Direct |
| Oct 1, 2024 | OTLK Outlook Therapeutics, Inc. | Award Stock Option (Right to Buy) | 71,169 | - | - | Direct |
| Oct 1, 2024 | OTLK Outlook Therapeutics, Inc. | Award Stock Option (Right to Buy) | 56,636 | - | - | Direct |
1-8 of 8 transactions